The greatest unknown if which reimbursement model for these high-cost therapies will gain supremacy, explained Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology.
The greatest unknown if which reimbursement model for these high-cost therapies will gain supremacy, explained Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology.
TranscriptWhat do you see in the future for reimbursement for high-cost therapies?
I think that the greatest unknown in this, and I think there are a lot of unknowns, is which model will gain supremacy. So, if I had to bet, I think there’s definitely going to be a performance-based aspect of it. Whether its shorter or long term, it’s still unclear because of the complexities of managing this over the longer term. I think there’s opportunities for new players like third-party administrators to help with some of the data capture and looking at people’s movement between plans and their outcomes if they leave a plan.
I think providers will have a piece in that, in monitoring patients and getting reimbursed for monitoring patients’ outcomes in ways maybe that they haven’t always had good reimbursement in the past. And then, the greatest unknown is the aggregate effect of all these new therapies as they gain approval. I think there’s dozens of therapies that potentially could be approved between now and 2025. One is the number of therapies and the other piece is the number of patients who are eligible and that total cost that will potentially be on the table. Whether people can bear that in the short term or need to move to new models is still unknown and a lot will play out as the approvals move forward.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More